<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Thallium-201: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Thallium-201: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Thallium-201: Drug information</div><div class="clear"></div><div id="topicText"><div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F28100668"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Radiopharmaceutical</li></ul></div>
<div class="block doa drugH1Div" id="F28100686"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Dose should be individualized; utilize the lowest dose necessary to obtain images.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="35c2ba49-dc66-407b-9311-b43de468ef7e">Myocardial perfusion</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Myocardial perfusion:</b>
<b>IV:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Planar scintigraphy:</i> 37 to 74 MBq (1 to 2 mCi)</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Single-photon emission computed tomography (SPECT):</i> 74 to 111 MBq (2 to 3 mCi)</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a7bcba8c-85b2-4783-ad04-46274fbbb984">Parathyroid hyperactivity localization</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Parathyroid hyperactivity localization:</b> Planar or SPECT: 75 to 130 MBq (2 to 3.5 mCi).</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50990871"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling.</p></div>
<div class="block doha drugH1Div" id="F50988159"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling.</p></div>
<div class="block doe drugH1Div" id="F56549549"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block adr drugH1Div" id="F29038059"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Frequency not defined.</p>
<p style="text-indent:-2em;margin-left:2em;">Cardiovascular: Cardiac arrhythmia, cerebrovascular accident, flushing, hypotension, myocardial infarction</p>
<p style="text-indent:-2em;margin-left:2em;">Central nervous system: Chills</p>
<p style="text-indent:-2em;margin-left:2em;">Dermatologic: Diaphoresis, pruritus, skin rash</p>
<p style="text-indent:-2em;margin-left:2em;">Gastrointestinal: Mild diarrhea, nausea, vomiting</p>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity: Anaphylactoid reaction</p>
<p style="text-indent:-2em;margin-left:2em;">Neuromuscular &amp; skeletal: Tremor</p>
<p style="text-indent:-2em;margin-left:2em;">Ophthalmic: Blurred vision, conjunctivitis</p>
<p style="text-indent:-2em;margin-left:2em;">Respiratory: Bronchoconstriction, dyspnea</p>
<p style="text-indent:-2em;margin-left:2em;">Miscellaneous: Fever</p></div>
<div class="block coi drugH1Div" id="F28100674"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">There are no contraindications listed in the manufacturer’s labeling</p></div>
<div class="block war drugH1Div" id="F28100675"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular events: Arrhythmias, bronchoconstriction, cerebrovascular events, chest pain, ECG abnormalities, hypotension or hypertension, and myocardial infarction (MI) have occurred due to pharmacologic agents used in conjunction with stress imaging. Appropriate measures for monitoring and resuscitation should be available during use.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity reactions: Anaphylactoid reactions (flushing, hypotension, pruritus, and diffuse rash) have been reported.</p>
<p style="text-indent:-2em;margin-left:4em;">• Local reactions: Local injection site reactions (eg, burning, pain, redness) may occur. Administer intravenously only to avoid local tissue accumulation and irradiation. Ensure proper catheter or needle position prior to and during injection.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Latex: The vial stopper in some products may contain latex.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special handling:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Radiopharmaceutical: Use appropriate precautions for handling, disposal, and minimizing exposure to patients and health care personnel. Use only under supervision of individuals with experience/training in the handling of radioactive materials approved by the applicable regulatory authority.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Administer thallous chloride Tl 201 injection close to calibration time to minimize the effect of higher levels of radionuclidic contaminants present at pre- and post-calibration dates.</p></div>
<div class="block foc drugH1Div" id="F27773338"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 37 MBq (1 mCi)/mL (1 ea [DSC]); 74 MBq (2 mCi)/mL (1 ea [DSC])</p></div>
<div class="block geq drugH1Div" id="F27773337"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F28326108"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Thallous Chloride TL 201 Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2 mci/mL (per each): $162.58 - $731.57</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52885650"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 37 MBq/mL (1 ea)</p></div>
<div class="block adm drugH1Div" id="F28100689"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">IV: Radiopharmaceutical; use appropriate precautions for handling and disposal.</p>
<p style="text-indent:-2em;margin-left:2em;">For IV administration only. Thallous chloride Tl 201 has a risk for extravasation. Confirm intravenous patency before injection.</p>
<p style="text-indent:-2em;margin-left:2em;">Myocardial perfusion imaging: For resting myocardial studies, start imaging 10 to 20 minutes after injection administration; to improve myocardial-to-background ratio images, ensure patients are injected upright (reduces hepatic and gastric thallium Tl-201 concentration) and in the fasting state. For exercise stress testing, administer injection at the start of maximum stress which is sustained for ~30 seconds after injection; start imaging within 10 minutes after administration to obtain maximum target-to-background ratios.</p>
<p style="text-indent:-2em;margin-left:2em;">Parathyroid hyperactivity localization: Administer injection before, with, or after a minimal dose of appropriate thyroid imaging agent (eg, sodium pertechnetate Tc 99m or sodium iodide I-123) to enable thyroid subtraction imaging.</p></div>
<div class="block use drugH1Div" id="F7734638"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Myocardial perfusion imaging:</b> Imaging with planar scintigraphy or single photon emission computed tomography (SPECT) for the diagnosis of coronary artery disease by localization of nonreversible defects (myocardial infarction), and reversible defects (myocardial ischemia) when used in conjunction with exercise or pharmacologic stress.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Parathyroid hyperactivity imaging:</b> Localization of sites of parathyroid hyperactivity pre- and postoperatively in patients with elevated serum calcium and parathyroid hormone levels.</p></div>
<div class="block mst drugH1Div" id="F7734634"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Other safety concerns:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Radiopharmaceutical: Use appropriate precaution for handling, disposal, and minimizing exposure to patients and healthcare personnel. Use under supervision of experienced personnel. Should be stored in original lead container or adequate radiation shield.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F25590685"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F25590682"><span class="drugH1">Drug Interactions</span>
<br/><br/><div class="clear"></div><p style="text-indent:0em;display:inline">There are no known significant interactions.</p></div>
<div class="block rep_considerations drugH1Div" id="F53623809"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Evaluate pregnancy status prior to use in females of reproductive potential.</p></div>
<div class="block pri drugH1Div" id="F28100671"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Animal reproduction studies have not been conducted. Thallous chloride Tl 201 has been shown to cross the placenta.</p></div>
<div class="block brc drugH1Div" id="F28100673"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Thallous chloride Tl 201 is excreted into breast milk. The manufacturer recommends advising patients who continue breast-feeding to express and discard milk for a minimum of 2 weeks after administration. Close contact with infant should be minimized if administered dose would result in an effective dose greater than 1 mSv (0.1 rem) to the infant.</p></div>
<div class="block pha drugH1Div" id="F28100679"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Radioactive diagnostic agent which decays by electron capture to mercury Hg 201 that can be detected by imaging. It is distributed to the myocardium, correlating to regional perfusion.</p></div>
<div class="block phk drugH1Div" id="F28100680"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution: Primarily distributed in the myocardium, thyroid, liver, kidneys and stomach</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Bi-exponential: Initial radioactive half-life: ~5 minutes; remainder ~40 hours; Biologic half-life: 2.4 days</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: Myocardium uptake: ~10 minutes</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (4% to 8% of injected activity within 24 hours); feces</p></div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference">
                  Thallous Chloride Tl 201 Injection [prescribing information] Maryland Heights, MO: Curium US LLC; December 2018.</div>
</li></ol></div><div id="topicVersionRevision">Topic 101540 Version 55.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
